Cytomel (Liothyronine) Cost in Montana 2026

What Does Liothyronine (Cytomel) Actually Cost in Montana in 2026?

Generic liothyronine tablets average about $35 per month at Montana retail pharmacies when paid out of pocket, compared to the $120 per month Pfizer list price for brand-name Cytomel. The gap is large. Pharmacy benefit managers negotiate contracts differently, so the price you see on a receipt varies by chain and by which discount card you present.

Liothyronine is the synthetic form of triiodothyronine (T3), the more metabolically active thyroid hormone. It has been FDA-approved since 1956 [1] and is prescribed either as monotherapy for hypothyroidism or as an adjunct to levothyroxine (T4) when patients continue to report fatigue and cognitive symptoms despite normal TSH. The clinical rationale for combined T4/T3 therapy was examined rigorously in Bunevicius et al. (NEJM 1999, N=33), which found that replacing 50 mcg of levothyroxine with 12.5 mcg of liothyronine improved mood and neuropsychological function compared to levothyroxine alone [2].

Pricing at specific Montana pharmacies tracked in early 2025 showed the following approximate cash-pay figures for a 30-day supply of generic liothyronine 25 mcg:

• Walmart (Billings, Great Falls, Missoula): $9 to $12 on the $4/$10 generic list
• Costco Pharmacy (Billings): $8 to $14 depending on quantity
• Independent pharmacies (Kalispell, Bozeman): $18 to $45 without discount card
• National chains (CVS, Walgreens) with GoodRx-equivalent card: $18 to $30

The dose prescribed most often in practice is 5 mcg to 25 mcg once or twice daily, so a patient on 25 mcg twice daily would need 60 tablets per month, which affects total cost [3].

The FDA's current liothyronine labeling specifies starting doses of 25 mcg daily for most adults, with titration upward in 25 mcg increments every one to two weeks based on clinical response and serum T3 levels [1]. Patients with cardiac disease typically start at 5 mcg daily given liothyronine's faster onset compared to levothyroxine [1].

The table below summarizes 2026 Montana price tiers by access pathway:

| Access Pathway | Estimated Monthly Cost | |---|---| | Brand Cytomel (Pfizer), no insurance | $120 | | Generic liothyronine, cash-pay (retail) | $35 | | Generic liothyronine, Walmart $4 list | $9 to $12 | | Compounded liothyronine (503A pharmacy) | $40 | | With commercial insurance (after copay) | $0 to $25 | | Montana Medicaid | Not covered |

Does Montana Medicaid Cover Liothyronine (Cytomel)?

Montana Medicaid does not currently cover Cytomel or its generic equivalent liothyronine for the adjunct hypothyroidism indication. This reflects a common Medicaid formulary stance across many state programs, which typically list levothyroxine as the preferred thyroid agent and treat liothyronine as non-preferred or non-covered unless a prescriber documents a specific medical necessity [4].

Montana Medicaid is administered under the Healthy Montana Plan and follows the Montana Department of Public Health and Human Services (DPHHS) preferred drug list (PDL). Levothyroxine sodium appears on the PDL at the lowest cost-sharing tier. Liothyronine does not have a listed preferred status, meaning claims are routinely denied without a prior authorization (PA) [5].

A PA request for liothyronine under Montana Medicaid would generally require documentation that:

1. The patient has documented hypothyroidism with persistently low free T3 despite adequate levothyroxine therapy.
2. An endocrinologist or physician has reviewed the case and recommended combination therapy.
3. Levothyroxine monotherapy has been tried for at least 90 days without resolution of symptoms.

Even with PA, approval is not guaranteed. Patients denied coverage should request a written denial and file an appeal within 30 days. The American Thyroid Association (ATA) 2012 guidelines state that "the combination of T4 and T3 may be considered as an alternative to monotherapy in selected patients" [6], and citing this in a PA letter may support the appeal.

Patients on Medicaid in Montana who need liothyronine and cannot obtain PA approval have three practical options: purchase generic tablets out of pocket (as low as $9 at Walmart), enroll in a manufacturer or pharmacy discount program, or request a compounded preparation from a 503A pharmacy at roughly $40 per month.

Is Compounded Liothyronine T3 Legal in Montana?

Compounded liothyronine T3 is legal in Montana when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Montana follows federal 503A rules under the Drug Quality and Security Act (DQSA) of 2013, which permit non-sterile compounding of liothyronine tablets or capsules for individual patients [7].

The FDA has not placed liothyronine on its list of bulk drug substances that may not be used in compounding, meaning a licensed Montana pharmacist may prepare customized doses. Common reasons patients choose compounded T3 include:

• Need for a dose not commercially available (e.g., 7.5 mcg or 10 mcg tablets, since commercial tablets come in 5 mcg, 25 mcg, and 50 mcg strengths only)
• Dye or filler sensitivities to commercial tablet excipients
• Preference for slow-release formulations, though the evidence base for compounded sustained-release T3 is limited [8]

One important clinical note: sustained-release compounded liothyronine has not demonstrated superiority over immediate-release liothyronine in controlled trials. A 2019 crossover study published in Thyroid (N=75) found no statistically significant difference in symptom scores between sustained-release and immediate-release T3 preparations [8]. Patients should discuss formulation choice with their prescriber rather than assuming compounded equals better.

503B outsourcing facilities, which can compound without patient-specific prescriptions, are generally not permitted to compound liothyronine for office stock under current FDA guidance [9]. Montana prescribers ordering compounded T3 must therefore send individual patient prescriptions to a licensed 503A pharmacy.

Montana Board of Pharmacy maintains a public license verification tool at mt.gov/dli/bsd/license/bsd_boards/pha_board. Patients can confirm a compounding pharmacy's active Montana license before transferring a prescription.

Which Insurance Plans Cover Liothyronine in Montana?

Commercial insurance plans in Montana cover liothyronine at varying tier levels, and cost-sharing ranges from $0 to $25 per month with a preferred generic tier placement to $50 or more at non-preferred tiers. The specific coverage depends on the plan's formulary year, the insurer, and whether the prescriber has filed a PA.

Montana's largest commercial insurers include Blue Cross Blue Shield of Montana, PacificSource, and SelectHealth. Each publishes an annual formulary [10]. For 2026, generic liothyronine appears on Tier 2 (preferred generic) on many plans, which translates to a copay of $10 to $20 per month after deductible. Brand-name Cytomel, if covered at all, typically sits at Tier 3 or Tier 4 with a copay of $40 to $100 per month.

Medicare Part D plans available in Montana in 2026 include several stand-alone PDPs. The CMS Medicare Plan Finder shows that generic liothyronine is covered on most Part D formularies, commonly at Tier 1 or Tier 2, with cost-sharing below $15 per month at preferred network pharmacies [11]. Patients should use the Plan Finder at medicare.gov to compare Part D options during open enrollment (October 15 to December 7 each year).

Key steps to confirm your Montana insurance coverage:

1. Call the member services number on your insurance card and ask specifically for the "formulary tier" for NDC 00071-0100-xx (brand Cytomel) or the generic equivalent.
2. Ask whether a PA is required and, if so, request the PA criteria in writing.
3. Have your prescriber's office submit clinical notes documenting the indication before the PA is reviewed.

The ATA and American Association of Clinical Endocrinologists (AACE) jointly published a 2022 framework recommending that insurers evaluate liothyronine coverage requests using objective laboratory criteria rather than symptom scores alone [6].

How to Get the Cheapest Liothyronine in Montana

The cheapest route to liothyronine in Montana depends on your insurance status, the pharmacy you use, and whether you are willing to use a discount card or patient assistance program. For most uninsured or underinsured patients, generic liothyronine at Walmart's $4/$10 generic program is the single lowest-cost option, at $9 for a 30-day supply or $12 for a 90-day supply in stores that carry the $10 tier [12].

GoodRx, RxSaver, and similar discount platforms negotiate rates at Montana retail pharmacies. GoodRx prices for generic liothyronine 25 mcg (30 tablets) in Montana zip codes ranged from $9 to $22 in January 2025 depending on pharmacy location and quantity [13]. These coupons cannot be combined with insurance, so patients must choose one or the other at the point of sale.

Pfizer's patient assistance program, Pfizer RxPathways, offers brand-name Cytomel at reduced or no cost to patients who meet income criteria (generally household income at or below 400% of the federal poverty level) [14]. The application is submitted online and requires proof of income and a prescription from a U.S.-licensed provider. Montana patients with income between 200% and 400% of the poverty level may qualify for discounted brand Cytomel rather than the free-drug tier.

NeedyMeds.org lists additional Montana-specific pharmacy assistance programs and state pharmaceutical assistance contacts. The Montana Department of Commerce does not operate a dedicated drug discount card program as of 2025, unlike some other states.

For patients already on commercial insurance, requesting a "formulary exception" in writing can move liothyronine from a higher tier to a lower tier if the prescriber documents that the generic is medically necessary and that the patient has a clinical reason to avoid levothyroxine monotherapy. This process is governed by the insurer's internal exception policy, which must comply with Montana insurance code and ACA non-discrimination provisions [15].

Can I Get Liothyronine via Telehealth in Montana?

Telehealth prescribing of liothyronine is permitted in Montana. A Montana-licensed prescriber who conducts a synchronous video or audio visit can legally write a liothyronine prescription for a Montana patient, provided the standard of care for evaluation is met [16].

Montana adopted expanded telehealth regulations during the COVID-19 public health emergency, and the legislature made many of those expansions permanent through HB 129 (2021). Audio-only telehealth visits are permitted for established patients. New patients typically require a video visit to allow the prescriber to conduct a clinical assessment adequate for initiating thyroid hormone therapy.

Before prescribing liothyronine via telehealth, a Montana-licensed provider should review:

• Recent TSH, free T4, and free T3 lab results (within the past 6 months at minimum)
• Prior thyroid history including any radioactive iodine treatment, thyroidectomy, or autoimmune diagnosis
• Current levothyroxine dose and duration
• Cardiac history (given liothyronine's chronotropic effects)

The American Thyroid Association's clinical guidelines note that "measurement of serum T3 is not routinely recommended for monitoring of hypothyroidism" but becomes relevant when combination therapy is being considered [6]. A telehealth provider should obtain free T3 before initiating liothyronine.

HealthRX clinicians licensed in Montana can evaluate patients for liothyronine therapy through a scheduled video visit, order baseline labs through a national reference laboratory with Montana draw sites, and transmit an electronic prescription to any Montana retail or compounding pharmacy. Prescriptions are not transmitted to pharmacies not licensed in Montana.

How Does the Pfizer Savings Card Work for Montana Patients?

The Pfizer savings card for brand-name Cytomel applies a fixed discount at the pharmacy counter, reducing the out-of-pocket cost for commercially insured patients. As of early 2025, the Pfizer RxPathways savings card can reduce the monthly cost of brand Cytomel to as low as $0 to $30 for eligible patients with commercial insurance that covers the drug [14].

The card does not work for patients covered by Medicare, Medicaid, or any other federal or state government health program. Montana Medicaid patients are explicitly excluded. The card is applied at the pharmacy like a secondary insurance card, and the pharmacist enters it after the primary insurance plan has processed the claim.

Steps to use the Pfizer savings card in Montana:

1. Enroll at pfizerrxpathways.com or ask your HealthRX provider to send you the enrollment link.
2. Download the card or print it. Present it alongside your insurance card at any participating Montana pharmacy.
3. If the pharmacy cannot process it electronically, call the number on the card for a manual override.

Patients who use the savings card with a non-formulary plan may still face high out-of-pocket costs because the card covers only a portion of the patient's share, not the full plan tier cost. In those cases, switching to generic liothyronine rather than brand Cytomel is almost always the more cost-effective choice given the $35 average Montana cash-pay price for the generic.

Monitoring and Safety Considerations for Liothyronine in Montana Patients

Initiating or adjusting liothyronine requires laboratory monitoring regardless of where you obtain the prescription. The FDA label specifies that serum TSH should be checked 4 to 6 weeks after any dose change [1]. Free T3 measurement is especially relevant for patients on combination therapy, as supraphysiologic T3 levels can increase the risk of atrial fibrillation and accelerate bone loss [17].

A prospective cohort study published in JAMA Internal Medicine (2017, N=188,167) found that exogenous thyroid hormone use was associated with a 34% higher risk of atrial fibrillation over a 10-year follow-up when TSH was suppressed below 0.1 mIU/L [17]. This risk was not confined to patients with hyperthyroidism; patients on replacement doses who drifted into subclinical hyperthyroidism also showed elevated rates. Montana prescribers following patients on liothyronine should maintain TSH within the normal reference range (0.4 to 4.0 mIU/L for most adults) unless treating thyroid cancer, where intentional suppression may be indicated [18].

Bone density monitoring with DEXA scan is reasonable for postmenopausal women and older men on long-term liothyronine, particularly if TSH trends below 0.4 mIU/L at any point during treatment [18]. The National Osteoporosis Foundation recommends DEXA at initiation and every 1 to 2 years thereafter for patients on medications that may reduce bone mineral density [19].

Rural Montana patients may face challenges accessing endocrinology follow-up. Telehealth platforms can fill this gap for TSH and free T3 monitoring, ordering labs at draw sites operated by Quest Diagnostics or LabCorp, both of which have patient service centers in Billings, Missoula, Great Falls, and Bozeman.